May 2nd 2024
In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Clinical Benefit of Cabozantinib Not Impacted by Age in Patients With RAI-Refractory DTC
October 7th 2021A subgroup analysis of the phase 3 COSMIC-311 study revealed no key differences in the survival and responses observed with cabozantinib based on the age of patients with RAI-refractory differentiated thyroid cancer.
Read More
Larotrectinib and The Risk of Fracture in TRK Fusion Thyroid Cancer
September 29th 2021Theodore W. Laetsch, MD, an attending physician with the Cancer Center at Children’s hospital of Philadelphia discusses if there is an increased risk of fractures with larotrectinib in patients with TRK fusion positive thyroid cancer.
Read More
BRAF/MEK Inhibitor Combination Shows Promise in Anaplastic Thyroid Cancer
September 28th 2021Principle study investigator Yuliya Mikheeva, MD, PhD, of Saint-Petersburg State University, discussed the combination of dabrafenib and trametinib for the treatment of anaplastic thyroid cancer in an interview with Targeted Oncology.
Read More
Multiple Trials Examined for RET-Targeted Therapies in MTC
September 27th 2021A 58-year-old man presented with a solitary nodule on the neck, occasional shortness of breath, and intermittent excessive fatigue. Twelve months after being treated with systemic therapy, symptoms occurred leading the oncologist to discover metastatic disease.
Read More
The Importance of Patient-Reported Outcomes in The LIBRETTO-001 Trial
September 23rd 2021Lori Wirth, MD, discusses the relevance of patient-reported outcomes from the phase 1/2 LIBRETTO-001 study in of selpercatinib in patients with RET-altered medullary thyroid cancer or advanced thyroid cancer.
Watch